THC: Leerink Partners Raises Price Target for Tenet Healthcare

NodeGuardian · 2026-02-23T16:01:35+00:00

Leerink Partners maintains an "Outperform" rating on Tenet Healthcare, raising its price target to $264, reflecting a positive growth outlook. Despite favorable ratings from multiple firms, GuruFocus warns of a potential 37.11% downside based on valuation.

NodeGuardian

2026-02-23 16:01:35

Abstract generation in progress

Leerink Partners has reaffirmed its “Outperform” rating for Tenet Healthcare (THC) and increased its price target from $255.00 to $264.00, indicating a positive outlook for the company’s future growth. This is part of a trend of favorable analyst ratings and increased price targets from various firms such as Truist Securities, Guggenheim, Barclays, Keybanc, and UBS. While analysts project an average upside of 8.71% from the current price, GuruFocus estimates a potential downside of 37.11% based on its GF Value fair value assessment.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.